WordNet

used to express refusal or denial or disagreement etc or especially to emphasize a negative statement; "no, you are wrong"
a negative; "his no was loud and clear"
referring to the degree to which a certain quality is present; "he was no heavier than a child" (同)no more
not in any degree or manner; not at all; "he is no better today"
quantifier; used with either mass nouns or plural count nouns for indicating a complete or almost complete lack or zero quantity of; "we have no bananas"; "no eggs left and no money to buy any"; "have you no decency?"; "did it with no help"; "Ill get you there in no time"
a bag that fills with air
a distensible membranous sac (usually containing liquid or gas) (同)vesica
the fifth of the seven canonical hours; about 3 p.m.

PrepTutorEJDIC

《名詞の前に置いて》『一つも』(『一人も,少しも』)・・・『ない』 / 《補語につけて》『決して・・・でない』 / 《省略文で》・・・なし;・・・お断り / 《話》少ししか(あまり)・・・ない / (肯定の問いに対して)『いいえ』;(否定の問いに対して)はい,ええ / 《not, norの前に挿入して》『いや』,否 / 《形容詞の前に置その形容詞を否定して》…どころではない / 《比較級の前に置いて》ちっとも…でない,…と全く同じ / 《… or no の形で》…であってもなくても / 《驚き・困惑・不信などを表して》とんでもない / 《単数形で》『拒否』,「『いいえ』」という返事 / 《複数形で》反対[投]票
(人間・動物の)襄(のう),ぼうこう,(魚の)浮き袋;気胞　嚢に似た物
活動的過ぎる,活発過ぎる

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 非神経性の下部尿路症状の治療におけるボツリヌス毒素の使用 use of botulinum toxin for treatment of non neurogenic lower urinary tract conditions
2. 男性における下部尿路症状 lower urinary tract symptoms in men
3. 小児における膀胱機能障害の病因および臨床的特徴 etiology and clinical features of bladder dysfunction in children
4. 尿失禁女性の尿流動態検査 urodynamic evaluation of women with incontinence
5. 女性における尿失禁の治療 treatment of urinary incontinence in women

The beta-3 adrenoceptor agonist, mirabegron relaxes isolated prostate from human and rabbit: new therapeutic indication?

Calmasini FB1, Candido TZ, Alexandre EC, D'Ancona CA, Silva D, de Oliveira MA, De Nucci G, Antunes E, Mónica FZ.
The Prostate.Prostate.2015 Mar 1;75(4):440-7. doi: 10.1002/pros.22930. Epub 2014 Nov 21.
BACKGROUND: Alpha1 (α1)-blockers, 5-alpha reductase and phosphodiesterase type-5 inhibitors are pharmacological classes currently available for benign prostatic hyperplasia (BPH) treatment. Mirabegron, a beta-3 adrenoceptor (β3-AR) agonist has been approved for the therapy of overactive bladder an
PMID 25417911

A review of detrusor overactivity and the overactive bladder after radical prostate cancer treatment.

Thiruchelvam N1, Cruz F, Kirby M, Tubaro A, Chapple C, Sievert KD.
BJU international.BJU Int.2015 Feb 13. doi: 10.1111/bju.13078. [Epub ahead of print]
There are various forms of treatment for prostate cancer. In addition to oncologic outcomes, physicians and increasingly patients are focusing on functional and adverse outcomes. Symptoms of overactive bladder (OAB), including urinary frequency, urgency, and incontinence, can occur regardless of tre
PMID 25684118

Huppertz ND1, Kirschner-Hermanns R, Tolba RH, Grosse JO.
BJU international.BJU Int.2015 Feb 13. doi: 10.1111/bju.13089. [Epub ahead of print]
OBJECTIVES: To generate real-time radio-telemetric urodynamic reference data of maximum detrusor pressure (Pdet max) , maximum flowrate (Qmax) and estimated grade of infravesical obstruction as well as for duration of detrusor contraction (DOC), in female Göttingen minipigs and to describe translat
PMID 25682883